BioCentury | Jun 24, 2020
Product Development

Action needed to prevent manufacturing bottlenecks on COVID-19 therapies

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...
BioCentury | May 8, 2020
Product Development

Getting real about COVID-19 data with Amy Abernethy and Mark McClellan

Responding to COVID-19 is forcing regulators, medical product developers and health systems to get real about real-world data and evidence as they reach for every available tool to learn about the disease and speed the...
BioCentury | Mar 19, 2020
Politics, Policy & Law

Former FDA Commissioners Gottlieb and McClellan propose actions to speed COVID-19 countermeasures

FDA should create task forces to facilitate the rapid development of point-of-care diagnostics, therapeutics and prophylactics for COVID-19, former FDA Commissioners Scott Gottlieb and Mark McClellan recommended in a working paper released Thursday. They also...
BioCentury | Jan 18, 2020
Product Development

Hard, measurable outcomes drive Express Scripts digital formulary

“I think that is reflective of how Express Scripts is moving forward.” The demonstration of hard clinical benefits and ROI for Express Scripts were the key elements that landed 10 digital platforms a spot on...
BC Extra | Sep 12, 2019
Politics & Policy

Proposal could clear obstacle to outcomes-based contracts

The Duke-Margolis Center for Health Policy has released a proposal that could remove the biggest barrier to the widespread adoption in the U.S. of value-based payment contracts for medicines. A technical fix to the Medicaid...
BC Extra | Sep 6, 2019
Company News

Cigna eases burden of high cost gene therapies; plan doesn’t account for lack of benefit

As the Medicaid best price rule continues to stymie attempts to move beyond one-time payments for gene therapies, some payers and pharmacy benefit managers are working to soften the blow for their clients and patients....
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BioCentury | Aug 31, 2019
Product Development

Digital health: payers are figuring out what it’s worth

Payers are starting to sort out how to reimburse for digital therapies and tools while they get up to speed on the new class of products. The answer is more of an “it depends” than...
BC Extra | Jul 11, 2019
Politics & Policy

White House kills rebate rule, likely to advance pricing index for Part B

A White House decision to withdraw a rule that would have eliminated rebates in Medicare Part D is the result of an internecine battle within the Trump administration over how to tackle drug pricing. It...
BC Extra | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...
Items per page:
1 - 10 of 71
BioCentury | Jun 24, 2020
Product Development

Action needed to prevent manufacturing bottlenecks on COVID-19 therapies

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...
BioCentury | May 8, 2020
Product Development

Getting real about COVID-19 data with Amy Abernethy and Mark McClellan

Responding to COVID-19 is forcing regulators, medical product developers and health systems to get real about real-world data and evidence as they reach for every available tool to learn about the disease and speed the...
BioCentury | Mar 19, 2020
Politics, Policy & Law

Former FDA Commissioners Gottlieb and McClellan propose actions to speed COVID-19 countermeasures

FDA should create task forces to facilitate the rapid development of point-of-care diagnostics, therapeutics and prophylactics for COVID-19, former FDA Commissioners Scott Gottlieb and Mark McClellan recommended in a working paper released Thursday. They also...
BioCentury | Jan 18, 2020
Product Development

Hard, measurable outcomes drive Express Scripts digital formulary

“I think that is reflective of how Express Scripts is moving forward.” The demonstration of hard clinical benefits and ROI for Express Scripts were the key elements that landed 10 digital platforms a spot on...
BC Extra | Sep 12, 2019
Politics & Policy

Proposal could clear obstacle to outcomes-based contracts

The Duke-Margolis Center for Health Policy has released a proposal that could remove the biggest barrier to the widespread adoption in the U.S. of value-based payment contracts for medicines. A technical fix to the Medicaid...
BC Extra | Sep 6, 2019
Company News

Cigna eases burden of high cost gene therapies; plan doesn’t account for lack of benefit

As the Medicaid best price rule continues to stymie attempts to move beyond one-time payments for gene therapies, some payers and pharmacy benefit managers are working to soften the blow for their clients and patients....
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BioCentury | Aug 31, 2019
Product Development

Digital health: payers are figuring out what it’s worth

Payers are starting to sort out how to reimburse for digital therapies and tools while they get up to speed on the new class of products. The answer is more of an “it depends” than...
BC Extra | Jul 11, 2019
Politics & Policy

White House kills rebate rule, likely to advance pricing index for Part B

A White House decision to withdraw a rule that would have eliminated rebates in Medicare Part D is the result of an internecine battle within the Trump administration over how to tackle drug pricing. It...
BC Extra | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...
Items per page:
1 - 10 of 71